PrecisionLife
Andy Malinowski, PhD is a Principal Disease Biologist at PrecisionLife where Andy develops drug discovery programs for genetics-derived targets linked to specific patient subgroups within chronic diseases. With a background in stem cells and epigenetics, Andy has held positions at Novo Nordisk, Helmhzentrum München, Imperial College London, and MRC London Institute of Medical Sciences, focusing on areas such as genomics, pharmacology, and cell signaling. Their work includes creating in vitro models, effect testing of small molecules/ligands, and studying cell-cell communication.